Since COVID, pharma manufacturers have shifted from lean, centralized supply chains toward regionalized hubs — balancing cost, flexibility, and geopolitical security to build resilience against future economic shocks.
In AI-driven biopharma R&D, success means spotting outside innovation. CSL's Nishtha Jain on building AI platforms for external innovation, keeping human judgment central, and evolving leadership amid AI and ethics.
Eli Lilly broke ground on a $6.5 billion Houston plant that will make Foundayo (orforglipron) and other medicines, creating over 600 jobs as part of its $50 billion push to reshore US drug manufacturing.
Milestone completes a $100 million investment cycle in New Jersey and supports Hovione’s long-term vision for a next-generation pharmaceutical development and manufacturing hub.
Explore how the flexible and efficient use of RABS and Isolators combined with operational expertise can address the challenges of aseptic processing.
Navigate complex CM decisions with the right excipients, practical testing access and process understanding.
Europe-wide 360° contract logistics for the pharmaceutical and healthcare industries are becoming even smoother—thanks to the new developments presented at CPHI in Milan.
CordenPharma is investing €80 million at its Caponago, Italy, site, adding a new facility and fill-finish lines to lift sterile injectable capacity to 500 million units/year, backed by shareholder Astorg.
The investment will reinforce the Bend site as a center of excellence for particle engineering and bioavailability enhancement and create a global manufacturing hub for commercial spray-drying.
Chairman of the Board of Directors Stefan Doboczky to take over operational leadership of the family-owned pharmaceutical technology and services group on April 1, 2027.
Northway Biotech is significantly expanding its development and manufacturing capacity with a new 3,500 sq. m facility featuring up to 20 independent cGMP manufacturing lines.
Samsung Biologics has published its formal offer prospectus to acquire PolyPeptide, deepening its push into peptide manufacturing as CDMOs race to expand capacity for GLP-1 and other peptide-based drugs.
New GMP (Good Manufacturing Practice) facility to meet increasing demand for lipid nanoparticle (LNP) development and clinical drug product manufacturing.
New APIs extend Wiley's gold-standard spectral data and analytical intelligence directly into lab, vendor, and platform workflows.
Samanta Cimitan will join Lonza as Chief Commercial Officer (CCO), Senior Vice President, and a member of the Extended Executive Committee, effective January 1, 2027.
Expansion strengthens integrated manufacture of amorphous solid dispersions (ASDs) by spray drying and tableting at a single site, accelerating development and simplifying supply.
Piramal Pharma strengthens its biologics CDMO business, converting Yapan Bio from associate company to subsidiary and expanding vaccine and biologics manufacturing capabilities.
The first personalized mRNA cancer therapy to beat the standard of care is now headed for regulators.
A pharma project demonstrates how MTP can accelerate integration while reducing validation effort.
Eurofins CDMO Alphora has expanded its kilolab and high-potency active pharmaceutical ingredient (HPAPI) development and manufacturing capabilities in Ontario.
CDMO Live Americas is where external manufacturing partnerships are made.
Novo Nordisk and Amazon Web Services (AWS) have partnered to accelerate drug discovery with AI. A co-innovation hub in London will facilitate efforts to reduce the time to market for future medicines.
CDMO Cambrex started construction on a new R&D facility at its Milan, Italy site. The $30 million investment adds advanced analytical development and process R&D capabilities.
The investment furthers the company's $40 billion commitment to invest in American innovation and manufacturing.
The partners will combine their unique capabilities to jointly develop, offer, and deliver integrated services in the Antibody-Drug Conjugates (ADC) segment for the global pharmaceutical and biotechnology industries.
The next phase of expansion for the Greenfield project in Sisslerfeld (Eiken, Switzerland) will be carried out as part of a strategic partnership. The total investment amounts to more than 500 million CHF.
Agreement advances new therapies through Engitix’s unique focus on the extracellular matrix (ECM).
An exclusive distribution agreement for Evonik Rexim amino acids strengthens Brenntag's role in the biopharma and API markets.
DCAT reports that FDA has selected seven companies for its new PreCheck Pilot Program, designed to encourage US-based drug manufacturing through earlier engagement and a more predictable regulatory path.
Olon has completed a major expansion at its Concord, Ohio facility, doubling production capacity and strengthening the site's role as a US manufacturing hub within its global development network.
Fujifilm Biotechnologies' Holly Springs, NC facility has been chosen as one of seven participants in the FDA's PreCheck Pilot Program, aimed at strengthening US pharmaceutical manufacturing and regulatory readiness.
Innexis plans to acquire the multi-user facility in Kundl, Tyrol, from Novartis.
Syngene International announced that Siddharth Mittal has assumed the role of Managing Director and Chief Executive Officer of the Company, effective 1 July 2026.
Russell Thomas, who has held senior roles at both organisations, takes on the joint CSO position as Symeres and Axxam push to offer clients a single pipeline spanning target screening to IND-ready drug candidates.
Rentschler Biopharma has appointed Torsten Woehr as Chief Executive Officer (CEO), effective August 1, 2026.
